

IN THE SPECIFICATION

Please replace the first paragraph on page 4 with the following new paragraph.

It has before been known to administrate rotigotine by passive transdermal therapeutic systems (TTS). Such passive transdermal therapeutic systems for the administration of rotigotine have been described for example in ~~WO 94/07568~~ WO 94/07468 and WO 99/49852. However, the rotigotine flux obtained with these passive transdermal therapeutic systems is not necessarily sufficient for all patients.